GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (FRA:YB4P) » Definitions » Institutional Ownership

Savara (FRA:YB4P) Institutional Ownership : 27.72% (As of Oct. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Savara Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Savara's institutional ownership is 27.72%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Savara's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Savara's Float Percentage Of Total Shares Outstanding is 83.25%.


Savara Institutional Ownership Historical Data

The historical data trend for Savara's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Institutional Ownership Chart

Savara Historical Data

The historical data trend for Savara can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30
Institutional Ownership 25.25 24.99 25.09 25.70 24.80 24.22 27.42 26.04 26.06 27.72

Savara Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Savara Business Description

Traded in Other Exchanges
Address
1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Savara Headlines

No Headlines